PLXP VS FWBI Stock Comparison

Performance

PLXP
10/100

PLXP returned -96.94% in the last 12 months. Based on the other stocks in its sector with an average return of -31.58%, its performance is below average giving it a grade of 10 of 100.

FWBI
10/100

FWBI returned -95.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Forecast

PLXP
75/100

1 analysts offer 12-month price forecasts for PLXP. Together, they have an average target of 0, the most optimistic forecast put PLXP at 0 within 12-months and the most pessimistic has PLXP at 0.

FWBI

"Forecast" not found for FWBI

Sentiment

PLXP
71/100

PLXP had a bullish sentiment score of 70.81% across Twitter and StockTwits over the last 12 months. It had an average of 9.26 posts, 0.97 comments, and 3.56 likes per day.

FWBI

"Sentiment" not found for FWBI

Technicals

PLXP
10/100

PLXP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

FWBI
10/100

FWBI receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

PLXP
10/100

PLXP has missed earnings 9 times in the last 20 quarters.

FWBI
10/100

FWBI has missed earnings 7 times in the last 20 quarters.

Profit

PLXP
41/100

Out of the last 20 quarters, PLXP has had 8 profitable quarters and has increased their profits year over year on 6 of them.

FWBI
10/100

Out of the last 20 quarters, FWBI has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

PLXP
30/100

PLXP has had a lower than average amount of volatility over the last 12 months giving it a grade of 29 of 100.

FWBI
54/100

FWBI has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

PLx Pharma Inc. Common Stock Summary

Nasdaq / PLXP

Healthcare

Drug Manufacturers—Specialty & Generic

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

First Wave BioPharma, Inc. Common Stock Summary

Nasdaq / FWBI

Healthcare

Biotechnology

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Power up your portfolio